Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-32 (Cancelled)

- 33. (Currently amended) A method for reducing colonization of enterohemorragic *Escherichia coli* (EHEC) in a mammal comprising administering to said ruminant a therapeutically effective amount of a composition comprising an EHEC cell culture supernatant.
- 34. (Currently amended) A method for reducing shedding of enterohemorragic *Escherichia coli* (EHEC) from a mammal comprising administrating to said ruminant a therapeutically effective amount a composition comprising an EHEC cell culture supernatant.
- 35. (New) The method of claim 33, wherein the mammal is a ruminant.
- 36. (New) The method of claim 35, wherein the ruminant is a bovine subject.
- 37. (New) The method of claim 33, wherein the composition further comprises an immunological adjuvant.
- 38. (New) The method of claim 33, wherein the EHEC is EHEC 0157:H7.
- 39. (New) The method of claim 33, wherein the EHEC is EHEC 0157:NM.
- 40. (New) The method of claim 37, wherein the immunological adjuvant comprises an oil-in-water emulsion.
- 41. (New) The method of claim 40, wherein the immunological adjuvant comprises a mineral oil and dimethyldioctadecylammonium bromide.
- 42. (New) The method of claim 41, wherein the immunological adjuvant is VSA3.
- 43. (New) The method of claim 42, wherein the VSA3 is present in the composition at a concentration of about 20% to about 40% (v/v).
- 44. (New) The method of claim 43, wherein the VSA3 is present in the composition at a concentration of about 30% (v/v).
- 45. (New) The method of claim 33, wherein the composition further comprises one or more recombinant or purified EHEC antigens selected from the group consisting of EspA, EspB, EspD, Tir and Intimin.
- 46. (New) The method of claim 45, wherein EspA + Tir comprise at least 20% of the cell protein present in the composition.

- 47. (New) The method of claim 37, wherein the composition further comprises one or more recombinant or purified EHEC antigens selected from the group consisting of EspA, EspB, EspD, Tir and Intimin.
- 48. (New) The method of claim 47, wherein EspA + Tir comprise at least 20% of the cell protein present in the composition.
- 49. (New) The method of claim 34, wherein the mammal is a ruminant.
- 50. (New) The method of claim 49, wherein the ruminant is a bovine subject.
- 51. (New) The method of claim 34, wherein the composition further comprises an immunological adjuvant.
- 52. (New) The method of claim 34, wherein the EHEC is EHEC 0157:H7.
- 53. (New) The method of claim 34, wherein the EHEC is EHEC 0157:NM.
- 54. (New) The method of claim 51, wherein the immunological adjuvant comprises an oil-in-water emulsion.
 - 55. (New) The method of claim 54, wherein the immunological adjuvant comprises a mineral oil and dimethyldioctadecylammonium bromide.
 - 56. (New) The method of claim 55, wherein the immunological adjuvant is VSA3.
 - 57. (New) The method of claim 56, wherein the VSA3 is present in the composition at a concentration of about 20% to about 40% (v/v).
 - 58. (New) The method of claim 57, wherein the VSA3 is present in the composition at a concentration of about 30% (v/v).
 - 59. (New) The method of claim 34, wherein the composition further comprises one or more recombinant or purified EHEC antigens selected from the group consisting of EspA, EspB, EspD, Tir and Intimin.
 - 60. (New) The method of claim 59, wherein EspA + Tir comprise at least 20% of the cell protein present in the composition.
 - 61. (New) The method of claim 51, wherein the composition further comprises one or more recombinant or purified EHEC antigens selected from the group consisting of EspA, EspB, EspD, Tir and Intimin.
 - 62. (New) The method of claim 61, wherein EspA + Tir comprise at least 20% of the cell protein present in the composition.